Renal Denervation: Is It Ready for Prime Time?
Name
11886_2019_1164_ReferencePDF.pdf
Size
960.09 KB
Format
Adobe PDF
Checksum (MD5)
e4d988419bba184e4e33d5db1b60e1fd
Author(s)
Lauder, Lucas
Wolf, Milan A.
Scholz, Sean S.
Hohl, Mathias
Mahfoud, Felix
Böhm, Michael
Date Issued
July 2019
Journal
Current Cardiology Reports
Publisher
Springer Science and Business Media LLC
Citation
Lauder, Lucas et al. "Renal Denervation: Is It Ready for Prime Time?" Current Cardiology Reports 21, 8 (July 2019): 80 © 2019 Springer Science Business Media, LLC
Version
Author's final manuscript
Abstract
Purpose of Review: Interventional cardiology and in particular the field of renal denervation is subject to constant change. This review provides an up to date overview of renal denervation trials and an outlook on what to expect in the future. Recent Findings: After the sham-controlled SYMPLICITY HTN-3 trial dampened the euphoria following early renal denervation trials, the recently published results of the sham-controlled SPYRAL HTN and RADIANCE HTN trials provided proof-of-principle for the blood pressure-lowering efficacy of renal denervation. However, these studies underline the major issue of patients’ non-adherence to antihypertensive medication as well as the need for reliable patient- and procedure-related predictors of response. Summary: The second generation of sham-controlled renal denervation trials provided proof of principle for the blood pressure-lowering efficacy of RDN. However, larger trials have to assess long-term safety and efficacy.
MIT Department
Massachusetts Institute of Technology. Institute for Medical Engineering & Science
Terms of Use
Article is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1007/s11886-019-1164-2
